1. Home
  2. FEIM vs TLSA Comparison

FEIM vs TLSA Comparison

Compare FEIM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frequency Electronics Inc.

FEIM

Frequency Electronics Inc.

HOLD

Current Price

$54.88

Market Cap

439.6M

Sector

Industrials

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.29

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEIM
TLSA
Founded
1961
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
439.6M
155.2M
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
FEIM
TLSA
Price
$54.88
$1.29
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$42.50
N/A
AVG Volume (30 Days)
229.2K
153.7K
Earning Date
03-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
316.95
N/A
EPS
0.41
N/A
Revenue
$69,811,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$21.73
N/A
P/E Ratio
$137.22
N/A
Revenue Growth
26.30
N/A
52 Week Low
$16.00
$0.73
52 Week High
$61.47
$2.60

Technical Indicators

Market Signals
Indicator
FEIM
TLSA
Relative Strength Index (RSI) 62.09 46.97
Support Level $49.46 $1.24
Resistance Level $59.68 $1.62
Average True Range (ATR) 3.94 0.11
MACD 1.49 0.01
Stochastic Oscillator 82.53 36.84

Price Performance

Historical Comparison
FEIM
TLSA

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: